Uncover the potential of active and passive investing on 6th October at 4pm. Register Now!
Last Updated : Aug 03, 2020 04:20 PM IST | Source: Moneycontrol.com

Buy Sanofi India; target of Rs 8815: ICICI Direct

ICICI Direct is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 8815 in its research report dated July 29, 2020.

Broker Research
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Sanofi India

Sanofi’s Q2CY20 revenues de-grew 5% YoY to Rs 710 crore mainly due to divesture of few products to Zentiva and Covid-19 impact on some therapies. Adjusting for Zentiva, continuing operations grew ~1% YoY. EBITDA margins improved 384 bps YoY to 24.9% due to lower other expenditure, better gross margins. Subsequently, EBITDA grew 12.3% YoY to Rs 177 crore. Adjusted PAT grew 38.8% YoY to Rs 135 crore. Delta vis-a-vis EBITDA was due to lower depreciation, tax rate and higher other income.


We maintain BUY with a target price of Rs 8815 (35x CY21E EPS of Rs 251.9).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

First Published on Aug 3, 2020 11:39 am